Drugs / MNV-BM-BLD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03384420 | Feb 2019 → Mar 2021 | Pearson syndrome, mitochondrial disease | Minovia Therapeutics Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MNV-BM-BLD | “A Phase I/II, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ Cells Enriched With Blood...” NCT03384420 ↗ |
| Modality | Cell therapy | “Autologous cd34+ Cells Enriched With Blood Derived Mitochondria” NCT03384420 ↗ |
| Route | Other | “Transplantation of autologous stem cell enriched with MNV-BLD” NCT03384420 ↗ |